Igy Immunologix India Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 21-06-2024
- Paid Up Capital ₹ 0.10 M
as on 21-06-2024
- Company Age 10 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.50 M
as on 21-06-2024
- Revenue -19.50%
(FY 2020)
- Profit -43.65%
(FY 2020)
- Ebitda -178.29%
(FY 2020)
- Net Worth 25.67%
(FY 2020)
- Total Assets 8.96%
(FY 2020)
About Igy Immunologix India
The Company is engaged in the Life Science Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.50 M.
Mona Gupta and Adinarayana Yerrapureddy serve as directors at the Company.
- CIN/LLPIN
U74900TG2014PTC093097
- Company No.
093097
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Feb 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Igy Immunologix India?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mona Gupta  | Director | 21-Feb-2014 | Current |
| Adinarayana Yerrapureddy | Director | 21-Feb-2014 | Current |
Financial Performance and Corporate Structure Insights of Igy Immunologix India.
Igy Immunologix India Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 19.5% decrease. The company also saw a substantial fall in profitability, with a 43.65% decrease in profit. The company's net worth Soared by an impressive increase of 25.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Igy Immunologix India?
In 2019, Igy Immunologix India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Zealous Health Private Limited
Active
6 years 9 months Mona Gupta and Adinarayana Yerrapureddy are mutual person
Excel Immunologix India Private Limited
Active 3 years 2 months Mona Gupta and Adinarayana Yerrapureddy are mutual person
Imkuraq Animal Health Private Limited
Active 7 years 10 months Mona Gupta and Adinarayana Yerrapureddy are mutual person
Pomona Agri Science Private Limited
Active 2 months 13 days Adinarayana Yerrapureddy is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 13 Jul 2016 | ₹2.50 M | Open |
How Many Employees Work at Igy Immunologix India?
Unlock and access historical data on people associated with Igy Immunologix India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Igy Immunologix India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Igy Immunologix India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
